Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.
Aug 12, 2021
0
370
After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.
Jul 27, 2021
0
9
Prostate cancer is the most common form of cancer among Canadian men and the third leading cause of cancer death. Abdominal obesity appears to be associated with a greater risk of developing aggressive prostate cancer. This ...
Jun 10, 2021
0
3
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery.
Jun 4, 2021
0
2
Overdiagnosis of breast cancer may be an inevitable consequence of the national population screening program, but the benefits of early diagnosis outweigh the harms of possible overtreatment, according to the authors of a ...
May 17, 2021
0
8
A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.
May 10, 2021
0
10
Immunobiologists in China have designed a synthetic T cell receptor for anticancer therapy, engineering the protein not only with a capability to seek and destroy solid tumors, but endowing this cancer fighting weapon with ...
Researchers at the Cheriton School of Computer Science have applied machine learning to identify tumor-specific antigens, which could help make personalized cancer vaccines practically feasible and more accurate.
Apr 30, 2021
0
6
City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, is now recruiting patients for a Phase 2 clinical trial to investigate whether pills containing ...
Apr 29, 2021
0
8
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional ...
Apr 11, 2021
0
4
